BioNTech SE: Chief Business Officer Sean Marett to Retire
Ticker: BNTX · Form: 6-K · Filed: Mar 7, 2024 · CIK: 1776985
| Field | Detail |
|---|---|
| Company | Biontech Se (BNTX) |
| Form Type | 6-K |
| Filed Date | Mar 7, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-retirement, management-change
Related Tickers: BNTX
TL;DR
BioNTech's Chief Biz Officer Sean Marett is retiring.
AI Summary
On March 7, 2024, BioNTech SE announced that Sean Marett, its Chief Business and Commercial Officer, will retire as planned from the Management Board. This marks the end of Marett's tenure with the company's leadership.
Why It Matters
The departure of a key executive like the Chief Business and Commercial Officer can signal shifts in company strategy or leadership structure.
Risk Assessment
Risk Level: low — This filing is an announcement of a planned executive retirement and does not involve financial performance or significant strategic changes.
Key Players & Entities
- BioNTech SE (company) — Registrant
- Sean Marett (person) — Chief Business and Commercial Officer
- March 7, 2024 (date) — Announcement Date
FAQ
Who is retiring from BioNTech SE's Management Board?
Sean Marett, Chief Business and Commercial Officer, is retiring as planned from the Management Board of BioNTech SE.
When was this retirement announced?
The announcement was made on March 7, 2024.
What is Sean Marett's role at BioNTech SE?
Sean Marett serves as the Chief Business and Commercial Officer.
Is this a planned retirement?
Yes, the filing states that Sean Marett will retire 'as planned'.
What form type is this SEC filing?
This is a Form 6-K report.
Filing Stats: 231 words · 1 min read · ~1 pages · Grade level 12.6 · Accepted 2024-03-07 08:41:50
Filing Documents
- form6-ksmarett7mar2024.htm (6-K) — 13KB
- a99_1xbiontechannouncespla.htm (EX-99.1) — 18KB
- image_0.jpg (GRAPHIC) — 102KB
- 0001776985-24-000015.txt ( ) — 172KB
From the Filing
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a16 OR 15d16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MARCH 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant's name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20F or Form 40F Form 20F Form 40F Indicate by check mark if the registrant is submitting the Form 6K in paper as permitted by Regulation ST Rule 101(b)(1) Indicate by check mark if the registrant is submitting the Form 6K in paper as permitted by Regulation ST Rule 101(b)(7) DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K On March 7, 2024, BioNTech SE announced that Sean Marett, Chief Business and Commercial Officer, will retire as planned from the Management Board of BioNTech. The press release is attached hereto as Exhibit 99.1. SIGNATURE Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioNTech SE By s Dr. Sierk Poetting Name Dr. Sierk Poetting Title Chief Operating Officer Date March 7, 2024 EXHIBIT INDEX Exhibit Description of Exhibit 99.1 BioNTech Announces Planned Retirement of Sean Marett